Landos is leveraging its AI-based integrated computational LANCE platform to discover and develop a pipeline of potentially first-in-class oral small molecule therapeutic candidates with differentiated profiles designed to address autoimmune, inflammatory, metabolic, and other diseases. The LANCE platform has enabled Landos to identify seven novel targets across thirteen indications to date that have the potential to restore the immune tolerance for patients with autoimmune disease

Home page of this offering   provided by Landos Biopharma